Orion Porfolio Solutions LLC Acquires 129,480 Shares of Avantor, Inc. $AVTR

Orion Porfolio Solutions LLC raised its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 83.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 285,419 shares of the company’s stock after purchasing an additional 129,480 shares during the period. Orion Porfolio Solutions LLC’s holdings in Avantor were worth $3,562,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Integrated Quantitative Investments LLC bought a new position in shares of Avantor during the third quarter valued at approximately $196,000. Skba Capital Management LLC raised its stake in Avantor by 96.2% in the third quarter. Skba Capital Management LLC now owns 62,497 shares of the company’s stock worth $780,000 after buying an additional 30,650 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Avantor by 22.8% in the third quarter. Dimensional Fund Advisors LP now owns 13,383,746 shares of the company’s stock worth $167,001,000 after buying an additional 2,482,519 shares in the last quarter. Royce & Associates LP lifted its holdings in Avantor by 25.0% during the third quarter. Royce & Associates LP now owns 51,772 shares of the company’s stock worth $646,000 after buying an additional 10,369 shares during the period. Finally, American Century Companies Inc. purchased a new stake in Avantor during the third quarter worth $19,032,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Insider Transactions at Avantor

In other news, Director Gregory T. Lucier acquired 50,000 shares of Avantor stock in a transaction dated Thursday, February 19th. The stock was purchased at an average cost of $9.16 per share, for a total transaction of $458,000.00. Following the completion of the purchase, the director directly owned 50,000 shares in the company, valued at $458,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gregory L. Summe bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average cost of $9.40 per share, with a total value of $940,000.00. Following the acquisition, the director directly owned 400,000 shares of the company’s stock, valued at approximately $3,760,000. This trade represents a 33.33% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.20% of the stock is currently owned by corporate insiders.

Avantor Stock Down 4.0%

NYSE:AVTR opened at $8.18 on Monday. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.70. Avantor, Inc. has a twelve month low of $8.14 and a twelve month high of $18.02. The company has a market cap of $5.58 billion, a PE ratio of -10.49, a P/E/G ratio of 3.21 and a beta of 0.97. The company’s 50 day moving average is $10.70 and its two-hundred day moving average is $11.84.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.21 by $0.01. Avantor had a negative net margin of 8.09% and a positive return on equity of 10.45%. The business had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period in the previous year, the firm posted $0.27 earnings per share. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.770-0.830 EPS. Analysts anticipate that Avantor, Inc. will post 1.06 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Bank of America downgraded Avantor from a “buy” rating to a “neutral” rating and set a $13.00 price target on the stock. in a report on Monday, December 15th. Morgan Stanley set a $10.00 price objective on Avantor in a research note on Friday, February 13th. TD Cowen reiterated a “hold” rating on shares of Avantor in a research note on Thursday, February 12th. Wells Fargo & Company reduced their target price on shares of Avantor from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Finally, Robert W. Baird set a $11.00 price target on shares of Avantor in a research report on Thursday, February 12th. Three equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $11.80.

Avantor News Roundup

Here are the key news stories impacting Avantor this week:

• Neutral Sentiment: Barclays reaffirmed an “underweight” rating and set a $8.50 price target (small upside relative to the current price), signaling limited near-term upside and continued cautious analyst positioning. Barclays Reaffirmation
• Neutral Sentiment: A recent Yahoo Finance piece outlines how analysts are resetting fair-value targets for Avantor, documenting the shift in analyst views but not pointing to an immediate positive catalyst. How The Avantor Story Is Shifting
• Negative Sentiment: Unusually large put-option volume: investors bought ~94,708 puts (up ~1,582% vs. typical), indicating significant bearish positioning or hedging activity that can amplify downside volatility.
• Negative Sentiment: Zacks Research issued a wave of cuts to quarterly and full-year EPS estimates, downgraded multiple forward-quarter forecasts and assigned AVTR a “Strong Sell” / Zacks Rank #5 — a material negative read on near-term fundamentals and sentiment. Zacks Adds AVTR to Strong Sell List

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.